Viz.ai has been granted FDA authorization for its AI-powered software, which is designed to analyse electrocardiograms (ECGs) and identify indications of hypertrophic cardiomyopathy (HCM). This rare and often undiagnosed condition involves the thickening or enlargement of the heart muscle, which can hinder the left ventricle's ability to efficiently pump blood throughout the body.
Despite its inconspicuous symptoms, HCM can lead to issues such as chest pain, shortness of breath, irregular heart rhythms, and valve dysfunction. Startlingly, it stands as one of the primary causes of sudden cardiac death for individuals below 35 years old.
Under the name Viz HCM, this AI algorithm has received de novo clearance from the FDA. It analyses 12-lead ECGs obtained in hospital settings to identify subtle markers of thickened cardiac tissue in adult patients. These markers are associated with minor alterations in the electrical signals that govern each heartbeat.
The software is slated to be integrated into Viz.ai's Cardio Suite, a collection of digital tools. It's important to note that the software doesn't provide an outright diagnosis of HCM; the condition is typically confirmed through an ultrasound examination. The development of Viz HCM received support from Bristol Myers Squibb, which has a vested interest in addressing HCM, the most prevalent inherited heart disease.
Bristol Myers Squibb made a substantial investment of $13 billion in late 2020 to acquire MyoKardia, a company specialising in mavacamten therapy, which works to hinder the progression of cardiac muscle tissue. This groundbreaking drug, named Camzyos, gained FDA approval in April 2022 and has demonstrated potential in minimising the need for surgical interventions in patients grappling with severe and obstructive HCM cases.
Click here to read the original news story.